cis-Atovaquone-d4

• UNSPSC Description:

  cis-Atovaquone-d4 is deuterium labeled Atovaquone. Atovaquone (Atavaquone) is a potent, selective and orally active inhibitor of the parasite’s mitochondrial cytochrome bc1 complex. Atovaquone is against human and  P. falciparum cytochrome bc1 activity with IC50 values of 460 nM and 2.0 nM, respectively. Atovaquone is an antimalarial agent and has the potential for the investigation of neumocystis pneumonia, toxoplasmosis, malaria, and babesia[1][2].

• Target Antigen:

  Antibiotic; Cytochrome P450; Isotope-Labeled Compounds; Parasite

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Anti-infection;Metabolic Enzyme/Protease;Others

• Field of Research:

  Infection

• Smiles:

  O=C1C([C@H]2CC[C@@H](C3=CC=C(Cl)C=C3)CC2)=C(O)C(C4=C1C([2H])=C([2H])C([2H])=C4[2H])=O

• Molecular Weight:

  370.86

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Nilsen A, et al. Quinolone-3-diarylethers: a new class of antimalarial drug.Sci Transl Med. 2013 Mar 20;5(177):177ra37.|[3]Schöler N, et al. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis.Antimicrob Agents Chemother. 2001 Jun;45(6):1771-9.

• Shipping Conditions:

  Room temperature